From rodent models of obesity to non-human primates and humans, their effectiveness to enhance body weight, glucose management, and lipid metabolism outperforms best-in-class GLP-1 monotherapies [126,127,128]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.